

Giovanni Barbara

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2272251/giovanni-barbara-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

10,316
citations

47
h-index

101
g-index

153
ext. papers

12,164
ext. citations

6.5
avg, IF

5.82
L-index

#	Paper	IF	Citations
126	Role of inflammation in pediatric irritable bowel syndrome.. <i>Neurogastroenterology and Motility</i> , 2022 , e14365	4	2
125	Managing the Inevitable Surge of Post-COVID-19 Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2021 , 116, 4-7	0.7	22
124	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. <i>American Journal of Gastroenterology</i> , 2021 , 117,	0.7	4
123	SeHCAT test for bile acid malabsorption: may the old become the gold one in the diagnostic burden of chronic diarrhea?. <i>Clinical and Translational Imaging</i> , 2021 , 9, 177-180	2	
122	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2021 , 9, 307-331	5.3	20
121	Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms. <i>Scientific Reports</i> , 2021 , 11, 8077	4.9	2
120	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. <i>Digestive and Liver Disease</i> , 2021 , 53, 202-209	3.3	3
119	Implications of SARS-CoV-2 infection for neurogastroenterology. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14104	4	16
118	Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. <i>Frontiers in Nutrition</i> , 2021 , 8, 718356	6.2	17
117	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14238	4	4
116	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021 , 2021, 2534975	2.8	2
115	Rifamycin vs placebo for the treatment of acute uncomplicated diverticulitis: A randomised, double-blind study. <i>GastroHep</i> , 2020 , 2, 295-308	1	2
114	Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders. <i>Nutrients</i> , 2020 , 12,	6.7	11
113	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13930	4	5
112	European Society of Coloproctology: guidelines for the management of diverticular disease of the colon. <i>Colorectal Disease</i> , 2020 , 22 Suppl 2, 5-28	2.1	45
111	Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. <i>Gut</i> , 2020 , 69, 1966-1974	19.2	25
110	Faecal microbial transplantation in IBS: ready for prime time?. <i>Gut</i> , 2020 , 69, 795-796	19.2	7

109	An international survey on clinicians' perspectives on the diagnosis and management of chronic intestinal pseudo-obstruction and enteric dysmotility. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13937	4	8
108	Nerve fiber overgrowth in patients with symptomatic diverticular disease. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13575	4	6
107	The Brain-Gut Axis and the Gender 2019 , 245-253		
106	Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry. <i>United European Gastroenterology Journal</i> , 2019 , 7, 815-824	5.3	4
105	μ-opioid receptor, κ-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13688	4	15
104	Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 23-29	1.4	1
103	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 57-66	1.4	7
102	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 39-44	1.4	0
101	Course of the Diverticular Disease: What is changing?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 11-16	1.4	0
100	Is gastroparesis a gastric disease?. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13562	4	23
99	Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2019 , 156, 46-58.e7	13.3	80
98	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1673-1676	6.9	37
97	Curriculum for neurogastroenterology and motility training: A report from the joint ANMS-ESNM task force. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13341	4	10
96	Demographic and clinical features distinguish subgroups of diverticular disease patients: Results from an Italian nationwide registry. <i>United European Gastroenterology Journal</i> , 2018 , 6, 926-934	5.3	9
95	Advancements in drug development for diarrhea-predominant irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 251-263	5.9	4
94	Allergic Proctocolitis Is a Risk Factor for Functional Gastrointestinal Disorders in Children. <i>Journal of Pediatrics</i> , 2018 , 195, 128-133.e1	3.6	15
93	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. <i>Digestive and Liver Disease</i> , 2018 , 50, 741-749	3.3	15
92	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018 , 155, 168-179	13.3	31

91	Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons. <i>Pain</i> , 2018 , 159, 1257-1267	8	22
90	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. <i>Gut</i> , 2018 , 67, 263-270	19.2	79
89	Glioplasticity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13232	4	10
88	Effect of CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. <i>United European Gastroenterology Journal</i> , 2018 , 6, 604-613	5.3	53
87	Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13192	4	73
86	Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13388	4	11
85	Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. <i>Environmental Microbiology</i> , 2018 , 20, 3201-3213	5.2	35
84	Funding for gastrointestinal disease research in the European Union. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 593-595	18.8	5
83	Protease-Activated Receptor 1 is implicated in irritable bowel syndrome mediators-induced signalling to human sensory neurons. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, OR3-3	0	
82	Recent advances in understanding non-celiac gluten sensitivity. <i>F1000Research</i> , 2018 , 7,	3.6	24
81	Probiotics in irritable bowel syndrome: Where are we?. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13513	4	22
80	5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein-coupled receptor D. <i>Science Signaling</i> , 2018 , 11,	8.8	20
79	Post-infectious IBS: Defining its clinical features and prognosis using an internet-based survey. <i>United European Gastroenterology Journal</i> , 2018 , 6, 1245-1253	5.3	21
78	Pre- and probiotic overview. <i>Current Opinion in Pharmacology</i> , 2018 , 43, 87-92	5.1	53
77	Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818771305	4.7	25
76	Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2017 , 49, 595-603	3.3	22
75	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 909-922	6.1	58
74	Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. <i>Gut</i> , 2017 , 66, 1252-1261	19.2	104

73	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. <i>United European Gastroenterology Journal</i> , 2017 , 5, 773-788	5.3	57
72	Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. <i>Neurogastroenterology and Motility</i> , 2017 , 29, e12928	4	10
71	Diagnostic challenges of symptomatic uncomplicated diverticular disease. <i>Minerva Gastroenterology</i> , 2017 , 63, 119-129	3	2
70	Randomised controlled trial of mesalazine in IBS. <i>Gut</i> , 2016 , 65, 82-90	19.2	67
69	Irritable bowel syndrome. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16014	51.1	429
68	Treatment of Diverticular Disease With Aminosalicylates: The Evidence. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S60-3	3	12
67	Interferon- β s increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 310, G439-47	5.1	32
66	A New Reliable Method for Evaluating Gallbladder Dynamics: The 3-Dimensional Sonographic Examination. <i>Journal of Ultrasound in Medicine</i> , 2016 , 35, 297-304	2.9	5
65	The Intestinal Microenvironment and Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016 , ,	13.3	164
64	Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers. <i>FEMS Microbiology Ecology</i> , 2016 , 92,	4.3	75
63	Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction. <i>Gastroenterology</i> , 2015 , 148, 771-782.e11	13.3	51
62	IBS: biomarkers for IBS: ready for prime time?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 9-10	24.2	11
61	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015 , 64, 1774-82	19.2	78
60	Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015 , 149, 433-44.e7	13.3	85
59	Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. <i>Gastroenterology</i> , 2015 , 148, 1002-1011.e4	13.3	94
58	Italian consensus conference for colonic diverticulosis and diverticular disease. <i>United European Gastroenterology Journal</i> , 2014 , 2, 413-42	5.3	112
57	Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. <i>Gastroenterology</i> , 2014 , 147, 69-77	13.3	61
56	Intestinal permeability--a new target for disease prevention and therapy. <i>BMC Gastroenterology</i> , 2014 , 14, 189	3	810

55	Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. <i>Neurogastroenterology and Motility</i> , 2014 , 26, 196-204	4	45
54	Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 352-8	3	39
53	Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. <i>Gastroenterology</i> , 2014 , 146, 1659-1668	13.3	93
52	Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 1147-55	4.6	33
51	Intestinal microbiota in functional bowel disorders: a Rome foundation report. <i>Gut</i> , 2013 , 62, 159-76	19.2	607
50	Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. <i>Neurogastroenterology and Motility</i> , 2012 , 24, 1118-e570	4	49
49	Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2012 , 24, 1134-e572	4	40
48	Clinical approach to diarrhea. <i>Internal and Emergency Medicine</i> , 2012 , 7 Suppl 3, S255-62	3.7	17
47	Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46 Suppl, S52-5	3	60
46	Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1290-8	0.7	144
45	The immune system in irritable bowel syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2011 , 17, 349-59	4.4	134
44	Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. <i>Diseases of the Colon and Rectum</i> , 2011 , 54, 1326-38	3.1	54
43	Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2011 , 23, 1084-91	4	39
42	Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , 2011 , 13, 308-15	5	86
41	In memoriam of a master of neurogastroenterology: Marcello Tonini (1944-2010). <i>Neurogastroenterology and Motility</i> , 2010 , 22, 942-943	4	
40	Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?. <i>Expert Review of Molecular Diagnostics</i> , 2010 , 10, 389-93	3.8	17
39	475j Nerve Growth and Plasticity in the Colonic Mucosa of Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2010 , 138, S-65-S-65	13.3	4
38	Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. <i>Transplantation Proceedings</i> , 2010 , 42, 15-8	1.1	40

37	Gut microbiota and related diseases: clinical features. <i>Internal and Emergency Medicine</i> , 2010 , 5 Suppl 1, S57-63	3.7	16
36	Postinfectious irritable bowel syndrome. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009 , 48 Suppl 2, S95-7	2.8	52
35	Biomarkers in IBS: when will they replace symptoms for diagnosis and management?. <i>Gut</i> , 2009 , 58, 1571-5	5.2	28
34	Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29 Suppl 1, 1-49	6.1	238
33	Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 245-52	6.1	103
32	Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. <i>American Journal of Gastroenterology</i> , 2009 , 104, 392-400	0.7	258
31	New perspectives in irritable bowel syndrome: introduction to part 2. <i>Digestive and Liver Disease</i> , 2009 , 41, 843	3.3	
30	Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. <i>Gastroenterology</i> , 2009 , 137, 1425-34	13.3	262
29	Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. <i>Digestive Diseases</i> , 2009 , 27 Suppl 1, 115-21	3.2	20
28	Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. <i>Gut</i> , 2009 , 58, 196-201	19.2	360
27	Serine proteases: new players in diarrhoea-predominant irritable bowel syndrome. <i>Gut</i> , 2008 , 57, 1035-7	19.2	10
26	Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008 , 2, 735-40	4.2	8
25	Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42 Suppl 3 Pt 2, S214-7	3	21
24	What is the effect of inflammation on intestinal function?. <i>Inflammatory Bowel Diseases</i> , 2008 , 14 Suppl 2, S140-4	4.5	5
23	Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. <i>Gastroenterology</i> , 2007 , 132, 26-37	13.3	556
22	Chronic intestinal pseudo-obstruction: manifestations, natural history and management. <i>Neurogastroenterology and Motility</i> , 2007 , 19, 440-52	4	125
21	Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues. <i>Digestive Diseases</i> , 2007 , 25, 245-8	3.2	18
20	Novel therapeutic targets for enteric nervous system disorders. <i>Trends in Pharmacological Sciences</i> , 2007 , 28, 473-81	13.2	49

19	Role for protease activity in visceral pain in irritable bowel syndrome. <i>Journal of Clinical Investigation</i> , 2007 , 117, 636-47	15.9	408
18	Functional gastrointestinal disorders and mast cells: implications for therapy. <i>Neurogastroenterology and Motility</i> , 2006 , 18, 6-17	4	140
17	Mucosal Barrier Defects in Irritable Bowel Syndrome. Who Left the Door Open?. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1295-1298	0.7	26
16	Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 449-58	6.9	144
15	Interactions between commensal bacteria and gut sensorimotor function in health and disease. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2560-8	0.7	217
14	East meets West: infection, nerves, and mast cells in the irritable bowel syndrome. <i>Gut</i> , 2004 , 53, 1068-9	19.2	17
13	New pathophysiological mechanisms in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20 Suppl 2, 1-9	6.1	135
12	Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. <i>Gastroenterology</i> , 2004 , 126, 693-702	13.3	1054
11	A role for inflammation in irritable bowel syndrome?. <i>Gut</i> , 2002 , 51 Suppl 1, i41-4	19.2	188
10	Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. <i>Gastroenterology</i> , 2001 , 120, 1729-36	13.3	78
9	Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after Salmonella infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 1127-31	6.1	45
8	Probiotics: could they turn out to be ineffective in irritable bowel syndrome?. <i>Digestive and Liver Disease</i> , 2000 , 32, 302-4	3.3	16
7	Stress, inflammation and the irritable bowel syndrome. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999 , 13 Suppl A, 47A-49A		37
6	Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 11653-8	11.5	156
5	Evidence that tachykinins are the main NANC excitatory neurotransmitters in the guinea-pig common bile duct. <i>British Journal of Pharmacology</i> , 1998 , 124, 1703-11	8.6	19
4	Unsuccessful octreotide treatment of the watermelon stomach. <i>Journal of Clinical Gastroenterology</i> , 1998 , 26, 345-6	3	36
3	Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. <i>Gastroenterology</i> , 1997 , 113, 1224-32	13.3	172
2	Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. <i>Gastroenterology</i> , 1996 , 110, 1036-42	13.3	539

- 1 Role of Smooth Muscle in Intestinal Inflammation. *Canadian Journal of Gastroenterology & Hepatology*, **1996**, 10, 249-253